- Home
- PENG vs EWTX Comparison
PENG vs EWTX Comparison
Compare PENG & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PENG
- EWTX
- Stock Information
- Founded
- PENG 1988
- EWTX 2017
- Country
- PENG Cayman Islands
- EWTX United States
- Employees
- PENG N/A
- EWTX N/A
- Industry
- PENG Semiconductors
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- PENG Technology
- EWTX Health Care
- Exchange
- PENG Nasdaq
- EWTX Nasdaq
- Market Cap
- PENG 1.3B
- EWTX 1.5B
- IPO Year
- PENG 2017
- EWTX 2021
- Fundamental
- Price
- PENG $22.81
- EWTX $14.31
- Analyst Decision
- PENG Strong Buy
- EWTX Buy
- Analyst Count
- PENG 8
- EWTX 9
- Target Price
- PENG $27.13
- EWTX $39.89
- AVG Volume (30 Days)
- PENG 1.4M
- EWTX 600.2K
- Earning Date
- PENG 07-08-2025
- EWTX 08-11-2025
- Dividend Yield
- PENG N/A
- EWTX N/A
- EPS Growth
- PENG N/A
- EWTX N/A
- EPS
- PENG N/A
- EWTX N/A
- Revenue
- PENG $1,342,020,000.00
- EWTX N/A
- Revenue This Year
- PENG $19.58
- EWTX N/A
- Revenue Next Year
- PENG $8.64
- EWTX N/A
- P/E Ratio
- PENG N/A
- EWTX N/A
- Revenue Growth
- PENG 14.09
- EWTX N/A
- 52 Week Low
- PENG $14.20
- EWTX $10.60
- 52 Week High
- PENG $25.94
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- PENG N/A
- EWTX 54.06
- Support Level
- PENG N/A
- EWTX $13.94
- Resistance Level
- PENG N/A
- EWTX $15.33
- Average True Range (ATR)
- PENG 0.00
- EWTX 0.62
- MACD
- PENG 0.00
- EWTX 0.10
- Stochastic Oscillator
- PENG 0.00
- EWTX 49.75
About PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.